复苏制药公司报告,2025年的Q4成果强劲,收入猛增至3 550万美元,其库存在AI驱动的药物进步和资金改善方面上升了12.3%。 Recursion Pharmaceuticals reported strong Q4 2025 results, with revenue surging to $35.5 million and its stock rising 12.3% on AI-driven drug progress and improved financials.

递归制药公司报告说,2025年的Q4成果强劲,收入为3 550万美元,比上一年的450万美元增加450万美元,原因是Roche和Genentech公司创下了3 000万美元的里程碑,萨诺菲公司的协作活动也有所增加。 Recursion Pharmaceuticals reported strong Q4 2025 results, with revenue of $35.5 million—up from $4.5 million year-over-year—driven by a $30 million milestone from Roche and Genentech and increased Sanofi collaboration activity. 该公司将其净损失从1.789亿美元减少到1.081亿美元,在贸易量增加的情况下,其股票增长了12.3%,达到3.965亿美元。 The company narrowed its net loss to $108.1 million from $178.9 million, and its stock rose 12.3% to $3.9650 amid elevated trading volume. AI驱动的平台加快了药物发现的速度,REC-4881显示,在第二阶段FAP试验中聚氨酯负担的中位数减少了43%。 The AI-driven platform enabled faster drug discovery, with REC-4881 showing a 43% median reduction in polyp burden in a Phase 2 FAP trial. 现金储备达到7.54亿美元,将跑道延长到2028年初,五个临床方案正在取得进展,预期2026年将作出重要决定。 Cash reserves reached $754 million, extending the runway into early 2028, and five clinical programs are advancing, with key decisions expected in 2026.